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Methamphetamine (MA) and 3, 4-methylenedioxymethamphetamine (MDMA) 
are abused drugs gaining popularity for recreational use.  Co- administering one of these 
drugs with an over the counter drug (OTC), polydrug use, is a growing concern.  This 
concern is due to possible drug- drug interactions that can affect the metabolism of the 
scheduled drugs resulting in toxic effects.  Another concern is how these interactions 
affect toxicology analysis. One type of interaction can cause a scheduled drug to 
accumulate at higher concentrations which can lead to toxicity.  This increase could cause 
higher detection of the parent drug thus possibly causing the results to be misinterpreted.  
Determining possible drug interactions between OTC drugs and scheduled drugs are 
therefore important for interpreting adverse effects.  This study will look at two common 
OTC drugs, two popular scheduled drugs, and the possible interactions that can occur 
between them. The question posed by this study is: Does exposure to OTC drugs, 
cimetidine and dextromethorphan, alter the metabolism and subsequent clearance 
of the scheduled drugs MA and MDMA? 
Cimetidine (CMT) and MDMA are inhibitors of CYP2D6 (Van et al., 2006) 
whereas dextromethorphan (DEX) and MA are reported substrates for the CYP2D6 
isozyme (Brown, 2001).  Inhibitors, lead to increased substrate drug effect
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caused by an increase in drug concentration (Brown, 2001; Cupp et al., 1998; Badyal et 
al., 2001).  Clemens et al. (2005) confirm an increase in adverse effects when MDMA 
and MA are taken concurrently.  These studies illustrate the problems associated with co-
administering drugs and their potential drug–drug interactions.  Drugs and Human 
Performance Fact sheets from the National Highway Traffic Safety Administration 
(2005) also report “potential inhibitors of the CYP2D6 isozyme could decrease the rate of 
methamphetamine elimination if administered concurrently, while potential inducers 
could increase the rate of elimination.” 
The main focus of this research is to determine the interactions between OTC 
drugs, CMT and DEX, and scheduled drugs, MA and MDMA when administered 
concurrently.  The types of interactions possible are inhibition of metabolism of the 
scheduled drug or OTC drugs, stimulation of metabolism for one or all of the drugs, or no 
interaction between the drugs administered together.  This is significant because drug 
interactions may lead to the misinterpretation of toxicology results.  The skewed results 
could be due to the combination of MA with another drug that inhibits or competes for an 
enzyme.  These results mislead the analyst and cause problems in the accurate 
interpretation of the data.   
Three assumptions are made in this study.  One assumption is there are 
interactions when the OTC drugs are co- administered with MA or MDMA.  Another 
assumption is that the primary metabolism of the drugs occurs via the P450 CYP2D6 
enzyme.  The third assumption is the metabolism of the scheduled drugs decreases 
therefore increasing the drug concentration with one or all of the different combinations.  
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These assumptions are presumed since the drugs are either inhibitors or substrates of 
CYP2D6. 
The limitation of this study is the non-use of human subjects.  Rats are a 
convenient and inexpensive model system for studying drug kinetics.  Initial studies 
utilize commercially available kits containing human CYP2D6 isozyme.  Rat studies 





REVIEW OF LITERATURE 
II.A. Cytochrome P450- CYP2D6 
 The cytochrome P450 (CYP) enzyme system is a superfamily of hemoproteins 
that catalyze the metabolism of numerous compounds (Badyal et al., 2001).  The 
enzymes mainly involved with metabolism are located in the liver, primarily the 
endoplasmic reticulum of hepatocytes (Brown, 2001).  But the enzymes are also found in 
other areas like the small intestine, kidney, lung and brain.  More than thirty CYP human 
isozymes have been identified.  The most common type of catalyst reaction (Figure 1) is 
the monooxygenase reaction, where one atom of oxygen is inserted into an organic 




 Figure 1. The CYP monooxygenase reaction.  Source: Ohkawa et al., 2002. 
 
 
The P450 name refers to the “pigment at 450 nm” which comes from the 
characteristic Soret peak formed by absorbance of light at wavelengths near 450 nm 
when the heme iron is reduced and complexed to carbon monoxide.  The naming for the 
specific gene includes the CYP root symbol, an Arabic numeral to denote the family, 
letters (A, B, C) to indicate the subfamily, and another Arabic numeral to specify the 
gene (Badyal et al., 2001).   
Nomenclature 
• Root: CYP 
• Family: CYP2 
• Subfamily: CYP2D 
• Gene: CYP2D6 
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Metabolism is characterized by two phases that increase substrate solubility 
allowing clearance from the body (Figure 2).  Cytochrome P450 is an important part of 
the phase I metabolism of drugs, which alters a molecule by transforming the nature of a 
functional group or adding a functional group to introduce or unmask polar bodies.  This 
includes: hydroxylation, oxidation, desulfuration, sulfoxide formation, deacetylation, 
deamination, nitro reduction, reduction, and dealkylation routes of metabolism.  Phase II 
metabolism is a conjunctive process that includes adding a gluconuride ester or sulfate to 








The CYP2D6 allele is located on chromosome 22 and comprises <5% of the total 
CYP proteins (Badyal et al., 2001).  This isozyme is the second largest metabolizer of 
drugs in the body at 19% (Figure 3).  It has been studied extensively due to its genetic 
polymorphisms and its large number of substrates (Badyal et al., 2001).  Due to the 
genetic polymorphism there are classifications for an individual to be either a poor 
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metabolizer, normal metabolizer, or an extensive metabolizer.  Poor metabolizers cannot 
metabolize certain drugs due to lacking of a gene for the isozyme.  Normal metabolizers 
can metabolize drugs since they have the appropriate gene (Brown, 2001).  Extensive 
metabolizers can metabolize drugs quicker than the other two classifications.  Poor 
metabolizers may not obtain the prescribed effect from a specific drug, or they may reach 




Figure 3.  The proportion of drugs metabolized by the different P450 enzymes.  




P450 isoforms can indirectly be induced or inhibited which can cause drug 
interactions to occur.  Enzyme induction occurs when a drug stimulates the synthesis of 
enzyme protein production, thus increasing the enzyme’s metabolizing capacity (Cupp et 
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al., 1998).  Enzyme inhibition occurs when there is competition with another drug for the 
binding site (Cupp et al., 1998) or decrease in enzyme protein.  Inhibition magnitude is a 
function of the inhibiting agent concentration and the affinity of the agent for CYP2D6 
(Brown, 2001).  CYP2D6 inducers include phenobarbital, and rifampicin; inhibitors 
include tricyclic antidepressants (Zoloft), selective serotonin reuptake inhibitors (Prozac), 
CMT, MDMA, and quinidine; substrates include tricyclic antidepressants (Elavil), MA, 
and DEX (Brown, 2001). 
 
II.B. Methamphetamine  
N, α-dimethylphenethylamine, methamphetamine or MA, is a derivative of 
amphetamine (AMP) and belongs to the AMP class (Logan, 2002).  MA is commonly 
accepted as more addictive and favored by drug addicts (Shoblock et al., 2003) and has 
greater central nervous system (CNS) efficacy than AMP.  This efficacy is most likely 
due to MA’s greater ability to penetrate the CNS.  Amphetamines represent a class of 
compounds, phenethylamines, which have varying degrees of sympathomimetic activity 
(Shoblock et al., 2003).  The sympathetic nervous system is stimulated by endogenous 
neurotransmitters [norepinephrine (NE), dopamine (DA), serotonin (5- HT)], and 
sympathomimetic drugs imitate the neurotransmitters’ actions (Logan, 2002).  
Amphetamines are stimulant drugs that affect the CNS by causing the neurotransmitter 
DA to be displaced from its storage vesicles in the nerve terminal.  This displacement 
results in the synaptic dopaminergic receptor to be hyperstimulated (Logan, 2002).  At 
higher doses of MA, DA and 5-HT, concentrations are decreased in the brain, due to a 
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reduction in the enzyme activity responsible for their synthesis, tyrosine hydroxylase and 
tryptophan hydroxylase, respectively (Logan, 2002).   
There are two forms of MA: the d-isomer and the l-isomer.  The d-isomer is the 
preferred form due to greater CNS stimulant effects (Logan, 2002).  MA is N-
demethylated to p-hydroxymethamphetamine (~15%) and the active metabolite AMP (4-
7%) via the CYP2D6 isozyme.  Then AMP is metabolized to p-hydroxyamphetamine and 
other metabolites (Logan, 2002; Moore, 2003).  Figure 4 illustrates the metabolic 
pathway for MA and AMP (Feldman et al., 1999).  MA is well absorbed orally and 
highly lipid soluble.  It has a volume of distribution (Vd) of 3-7 L/ kg and a 
bioavailability of ~67%.  In humans, peak plasma concentration of 0.020 mg/ L at 2.6 h 
can be reached with a single oral dose of 0.125 mg and a half-life of 7-10 h (Logan, 2002; 
Moore, 2003).  MA is excreted in the urine 30- 54% unchanged, while 10% of the dose is 
excreted as AMP (Logan, 2002).   Elimination of MA and AMP are dependent on urinary 
pH; urinary acidification decreases the half-life and alkalization increases the half- life.  

















Figure 4.  MA and AMP metabolism schematic.  Reproduced with modifications 








Table 1. Pharmacokinetics summary for each drug 


















CYP2D6 0.125 mg 0.02 mg/ L 
@ 3.6 h 
7- 10 
h 
3-7 L/ kg 
MDMA MDA CYP2D6 1.5  mg 0.33 mg/ L 
@ 2.0 h 






L @ 1 h 




CYP2D6 30 mg <5 ng/ mL 
@ 4 h 
2- 4 h 5.0-6.4 




AMP was first synthesized in 1887.  In the 1920s it was used as a nasal 
decongestant to replace ephedrine and marketed in the 1930s as a Benzedrine inhaler.  Its 
ability to treat narcolepsy, hyperactivity in children and as a stimulant was quickly 
recognized.  In the late 1940s and 1950s AMP and related drug use reached epidemic 
quantities due to its use by soldiers, factory workers, and prisoners of war.  After World 
War II, Japanese marketed AMP and other related drugs like MA without a prescription 
thus increasing use and abuse. MA abuse became a social problem in the subsequent 
decades after WWII.  The Controlled Substances Act with the five levels of scheduling 
was enacted in 1986.  Due to increasing abuse, MA/ AMP’s highly addictive potential, 
and some medicinal use led to the classifications of MA and AMP as DEA schedule II 
controlled substances. 
Currently MA is an easily obtainable drug and is relatively easy to make due to 
the availability of the ingredients.  Many of the ingredients are found in OTC drugs 
containing ephedrine or pseudoephedrine and household products like hydrochloric acid, 
drain cleaner, battery acid, lye, lantern fuel, antifreeze, and red phosphorous 
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(http://www.kci.org/meth_info/faq_meth.htm).  Also the internet provides access to 
recipes to make MA at home.  Therefore most street MA is made in clandestine 
laboratories greatly increasing its availability.  This availability is a main reason why MA 
has become the drug of choice for stimulant abusers.   
 
 




• increased blood pressure 
• increased respiration rate 
• elevated temperature 
• palpitations  
• irregular heartbeat  
• bronchial muscle dilation 
• vasoconstriction  
• bladder contraction  
• dry mouth 
• diarrhea  
• nausea  
• abdominal cramps  
• loss of appetite  
• twitching  
• pallor  
• dilated pupils  
• horizontal gaze nystagmus at 
high doses 
• faster reaction time  
• increased strength  
• tooth decay 
• increased blood glucose levels 
• euphoria 
• intensified emotions 
• increased feeling of self- 
esteem and well being 
• excitation 
• exhilaration 
• rapid flight of ideas 
• increased libido 
• rapid speech 





• reduced fatigue or drowsiness 
• increased alertness 
• sensations of extreme physical 





• poor impulse control 





3, 4-Methylenedioxymethamphetamine, MDMA or ecstasy, is a recreational illicit 
drug that is very popular at all-night parties or raves.  MDMA is an analog of MA formed 
by methylenedioxy substitution (Logan et al., 2003), and belongs to the AMP class.  
MDMA is also structurally similar to mescaline (Oesterheld et al., 2004) and 
methylenedioxyamphetamine, MDA, (Logan et al., 2003).  MDMA affects several 
neurotransmitter systems including NE, DA, 5-HT, and the neurotransmitter γ- amino 
butyric acid, GABA, (Logan et al., 2003).  MDMA is a strong and selective 5- HT 
neurotoxin in numerous animal species, including non- human primates (Casco et al., 
2005).  In rats, MDMA stimulates 5-HT release which causes 5- HT synaptic 
concentrations to increase and depletion of 5- HT presynaptic stores (Logan et al., 2003).  
This process is believed to result from MDMA’s effect in reversing the 5-HT uptake 
transporter (Logan et al., 2003).   
There are two forms of MDMA: the R (-)-isomer and the more potent neurotoxin, 
the S (+)-isomer.  MDMA is O-demethylated to 3, 4-dihydroxymethamphetamine, 
HHMA, via CYP2D6 (Escobedo et al., 2004; Oesterheld et al., 2004) and N-
demethylated to the active metabolite MDA via CYP1A2 and CYP2D6 (Logan et al., 
2003).  It is a potent mechanism based (irreversible inhibitor) of CYP2D6 (Van et al., 
2006).  Figure 5 illustrates the metabolism schematic for MDMA (Escobedo et al., 2004).  
MDMA is well absorbed orally (Spiller, 2004) and soluble in water with a Vd of ~4.9 L/ 
kg (De Letter et al., 2002). In humans, it reaches peak plasma concentrations of 0.33 mg/ 
L at 2 h with an oral dose of 1.5 mg and a half-life of ~7 h (Logan et al., 2003).  MDA 
plasma concentrations peak later at 4-6 h and do not exceed 5% of the concentration of 
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the parent compound (Logan et al., 2003).  MDMA is excreted in the urine 65% 
unchanged (Spiller, 2004). Table 1 summarizes the pharmacokinetics. 
 
 
Figure 5.  MDMA metabolism schematic shown in part; HHMA: 3, 4-
dihydroxymethamphetamine, HMA: 4-hydroxy-3-methoxyamphetamine, HHA: 3, 4-




MDMA was first synthesized as an appetite suppressant in 1914 by Merck, but 
never marketed as such.  During the 1970s and 1980s, MDMA became popular as an 
adjunct for psychotherapy, but was never approved by the FDA.  MDA was originally 
termed as ecstasy (the active metabolite) and is related to saffrole.  It is used as a 
psychoactive agent in mace.  It was first synthesized in 1910 and has been used as an 
anorexiant, antitussive, and ataractic or tranquilizers.   It was abused in the 1960s and 
1970s for its psychoactive and hallucinogenic properties and therefore, it and MDMA 
(due to structural similarity) were classified as DEA schedule I controlled substances 
with no medicinal uses.  
Casco et al. (2005) provided evidence to support long-term electrophysical 
abnormality in MDMA users and suggested that typical recreational doses of MDMA are 
enough to cause long-term altered cortical activity in humans.   MDMA and MA when 
taken concurrently can produce greater adverse effects, dependent on the order of 
administration.  If MA is administered after MDMA, this can lead to greater 
hyperthermia and greater depletion of 5- HT compared to MDMA administered after MA 
(Clemens et al., 2005).  Clemens et al. (2005) also report an increase in adverse effects 
when MDMA and MA are taken concurrently.   This information is important to drug 







  Table 3. Physiological, psychological and positive effects of MDMA 
Physiological  
 
Psychological Positive Effects 
• increased blood 
pressure 
• increased heart rate 
• peripheral 
bronchodilation 
• vasoconstriction  
• nausea  
• dehydration  
• jaw clenching 
• blurred vision 
• vomiting 
• tachycardia 
• dry mouth 
• bruxism 
• muscle tension 
• increased sweating 
• ataxia 
• pupillary dilation 
• nystagmus 
• appetite suppression 
• urinary urgency 




• catatonic stupor 
• motor ticks 
• hallucinations 
• enhanced mood 




• desire to be in motion 
• insomnia 








• anxiety  




• empathy  
• changes in 
cognitive or mental 
associations 
• euphoria or elation 




 (Logan et al., 2003; NIDA Info facts: MDMA 2006)   
 
II.D. Cimetidine 
Cimetidine (CMT) is used as a treatment for acid reflux disease, heartburn, and 
ulcers.  CMT is available over the counter only as Tagamet®. CMT blocks the H2 
histamine receptors in the parietal cells of the stomach (Jantratid et al., 2006), thus 
reducing the amount of stomach acid.    CMT is a compound that can directly bind to the 
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cytochrome P450 heme iron reactive site thus inhibiting all cytochrome-dependent phase 
I enzyme activity (Liska, 1998).  Therefore, CMT has been associated with many drug-
drug interactions involving the inhibition of this isozyme (Park et al., 2005; Madeira et 
al., 2004).  One study shows CMT combined with MA causes “increased levels of 
methamphetamine and amphetamine in the brain of rats” (Suzuki et al., 1987).  This 
study suggests that increased levels of MA and AMP are due to inhibition of CYP2D6 by 
CMT.   
CMT is metabolized by the P450 enzymes, and its major metabolite is an S-oxide 
(Lu et al., 1998).  Figure 6 illustrates the metabolism schematic of CMT (Rendic, 1999).  
CMT is slightly soluble in water, 11.4 mg/ mL at 37°C with a pH of 9.3 (Jantratid et al., 
2006).  The Vd is ~0.8-1.39 L/ kg and bioavailability is between 56-68% (Jantratid et al., 
2006).  Tagamet® product information (2005) report peak blood levels in humans of 0.5-
1.1 mg/ L with doses of 75-117 mg.  The half-life of CMT is 2.0 h and 1.7 h for the 
metabolite, S-oxide (Larsson et al., 1982). CMT is excreted 70% unchanged and ~19% as 































• drowsiness  
• tiredness 
• rash 
• muscle pain 
• enlargement of the breasts 
• impotence (usually seen in 
patients on high doses for 
prolonged periods) 
• decreased white blood cell 
counts 
• irregular heartbeat 
• skin reactions 
• visual changes 
• allergic reactions 
• hepatitis 
• confusion 
• hallucinations (usually in 
elderly or critically ill 
patients)   





Dextromethorphan (DEX) is an antitussive used in cold and cough medications to 
relieve nonproductive coughs (Abdul Manap et al., 1999).   DEX is considered a 
dextrorotary morphinan because it does not bind to opioid receptors, thus it has no 
analgesic activities; however, it does bind to a site associated with sigma-site ligands and 
also to the phencyclidine (PCP) N-methyl-D-aspartate (NMDA) glutamate receptor 
channel site (Nicholson et al., 1999).  DEX has been used at higher doses as a 
recreational drug that produces dissociative effects similar to PCP and ketamine 
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(Nicholson et al., 1999; Lotrich et al., 2005).  Also at higher concentrations, DEX is a N-
methyl-D-aspartate (NMDA) antagonist like PCP and ketamine (Lotrich et al., 2005).  
Since 1975 the popularity and abuse of DEX has been recognized but it has not been 
placed on the Controlled Substances Act (Center for Substance Abuse Research, 2005).   
DEX is a substrate for CYP2D6 and may cause drug-drug interactions when taken 
in combination with other CYP2D6 substrates or inhibitors. It can also be used to 
determine what type of metabolizer an individual is with regards to CYP2D6 activity.  
This is measured by how much of the active metabolite, dextrorphan (DOR), is formed 
(Magarey, 1997).  One study showed DEX and DOR decreased MA self- administration 
at doses <30 mg/ kg in rats (Glick et al., 2001).  This study suggests that taking DEX 
with MA decreases levels of MA.  Another study showed an interaction between DEX 
and an inhibitor, quinidine, of CYP2D6.  Quinidine inhibited the metabolism of DEX, 
thus increasing the parent compound to metabolite ratio (Abdul Manap et al., 1999).   
DEX is O-demethylated to DOR, 20%, (Witherow et al., 1999) via CYP2D6 
(Abdul Manap et al., 1999).  Figure 7 illustrates the metabolism schematic for DEX (Min 
et al., 1999).  DEX is soluble in water (1.5 g/ 100 ml at 25°C) with a Vd (for dogs) of 5.0-
6.4 L/ kg (no data available for human Vd; Magarey, 1996).  In humans, peak plasma 
levels <5 ng/ mL at 4 h are reached with a dose of 30 mg and a half- life of 2-4 h 
(Magarey, 1996).  DEX is excreted in the urine ~11% unchanged (Magarey, 1996).   
Table 1 summarizes the pharmacokinetics. 
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Figure 7.  DEX metabolism schematic reproduced from University of Colorado 


























• blurred vision 





• shakiness and unsteady walk 
• slowed breathing 
• constipation 
• headache 
• stomach pain 
• ataxia 
• respiratory depression 
• tachycardia 










• CNS stimulation 
• lethargy 
(Magarey, 1996; Nicholson et al., 1999; Medline plus Drug Info, 2003)   
 
II.F. Summary 
 MA and MDMA are becoming increasingly popular drugs, thus polydrug use is a 
growing concern especially with OTC drugs like CMT and DEX.  The concern is due to 
the types of interactions these combinations would have on the user and the problems for 
toxicology testing.  Determining the effects between OTC drugs and scheduled drugs are 
important in preventing adverse effects.  The purpose of this study is to determine if 
interactions occur between two over the counter drugs, cimetidine and dextromethorphan, 
and two scheduled drugs, methamphetamine and 3, 4-methylenedioxymethamphetamine, 
and if interactions do occur, then what are those interactions? 
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II.F.i. Hypothesis 
 The hypothesis for this study is that two OTC drugs, CMT and DEX, will alter the 
metabolism of two abused drugs, MA and MDMA resulting in increased plasma levels of 
MA and MDMA.  
  
II.F.ii. Aims 
The aims for this study include: 
• Potential interactions of MA or MDMA and OTC drugs using purified human 
CYP2D6 
• In vivo studies will examine the effects of the combinations of the OTC and 
scheduled drugs: 1) MA on CYP2D2 activity and 2) MA concentration following 







Methamphetamine HCl, 3, 4-methylenedioxymethamphetamine HCl, cimetidine, 
dextromethorphan HBr, acetonitrile, dimethyl sulfoxide (DMSO), 3-[2-(N, N-diethyl-N-
methylamino) ethyl]-7-methoxy-4-methylcoumarin (AMMC) were purchased from 
Sigma Chemical Company (St. Louis, MO).  The high throughput inhibitor screening kit 
CYP2D6/ AMMC was purchased from BD Biosciences Gentest
TM
 (Woburn, MA).  The 
P450 HTS kit supplies the required components including: insect cell microsomes 
(Supersomes®) made from human baculovirus insect cell expressing human CYP2D6 
(CYP2D6*1 + P450 reductase), nonfluorescent substrate, fluorescent metabolite, control 
insect cell membrane protein, cofactors (1.3 mM NAPD+, 66 mM MgCl2, and 66 mM 
glucose 6-phosphate), glucose 6-phosphate dehydrogenase (40 Units/ ml in 5 mM sodium 
citrate buffer (pH 7.5)), reaction buffer solution (0.5 M potassium phosphate, pH 7.4, 
filter sterilized), stop solution reagent (0.5 M Tris base reagent, filter sterilized), CYP2D6 
positive control inhibitor (quinidine), and NAPDH regenerating system. 
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III.A.i. HTS Kit Substrates 
AMMC, 3-[2-(N, N-diethyl-N-methylamino) ethyl]-7-methoxy-4-
methylcoumarin, (Figure 6) is a nonfluorescent substrate that demethylates to the 
fluorescent metabolite AHMC, 3-[2-(N, N-diethylamino) ethyl]-7-hydroxy-4-
methylcoumarin hydrochloride, (Figure 7) which was used with the human baculovirus 
















Figure 9.  AHMC structure. The fluorescent product, AHMC, is produced by the 




III.B. In vitro Inhibition Studies 
CYP2D6/ AMMC high throughput assay kits screen for potential inhibitors of 
CYP2D6 catalytic activity.  Quinidine is a known potent inhibitor of CYP2D6 and used 
as the control compound to determine intra- and inter- assay variability.  Each test 
compound and quinidine was assayed to determine the inhibition of the enzyme for that 
compound.  These compounds were serially diluted (1:3) from highest concentrations (20 
µM) to lowest concentrations (3 nM) and pre-incubated at 37
o
C for 10 min. The enzyme/ 
substrate mix contains AMMC, the nonfluorescent substrate that produces the fluorescent 
metabolite AHMC.  The enzyme/ substrate mix was added to quinidine and each test 
compound well, and then incubated at 37
o
C for 30 min.  During incubation AMMC 
demethylates to AHMC via CYP2D6.  The AHMC fluorescence was measured using a 
plate reader and inhibition of the enzyme was calculated from the fluorescent values 
(Figure 10). The fluorescence in each well was determined using a Synergy HT Multi 
Detection microplate reader (Bio-TEK®
 
Instruments, Inc., Winkooski, VT) with KC4 
software (Bio-TEK®
 
Instruments, Inc., Winkooski, VT).  AHMC was measured at 
excitation/emission wavelengths of 360 nm/ 460 nm. The CYP2D6 assay was run four 





Figure 10.  CYP2D6 assay schematic: AMMC is metabolized by recombinant 
human CYP2D6 to AHMC.  IC50 values were calculated from the reduced AHMC 
fluorescence upon addition of increasing concentrations of quinidine or a test compound.   
IC50 is the inhibitor concentration that causes a 50% decrease in enzyme activity. 
(Adapted from Krippendorff et al., 2007) 
   
 
Stock solutions (1 mM) of CMT, DEX, MA and MDMA were each prepared in 
HPLC-grade acetonitrile prior to being serially diluted for CYP2D6 assay.  All 
fluorescent assays were performed in black 96-well reading plates with flat clear bottoms 
to prevent fluorescence bleed over to adjoining wells and contamination of first readings 
(BD Falcon
TM 
Assay plates, Franklin Lakes, NJ).  Test groups for this assay were: CMT, 
DEX, MA, MDMA, CMT/ MA, CMT/ MDMA, DEX/ MA, DEX/ MDMA, CMT/ DEX/ 
MA, and CMT/ DEX/ MDMA.   
Prior to initiation of the assay, NAPDH-cofactor mix was prepared by adding 1.5 
ml of cofactors, 1.2 ml of glucose 6-phosphate dehydrogenase and 0.8 ml of control 
 28 
insect cell membrane protein to 117 ml of water (total volume 120 ml).  The NAPDH-
cofactor mix (144 µl) was pipetted into well 1 (Table 6) of each test compound and 
quinidine row.  Cofactor/ acetonitrile mix was prepared by using 96 ml of the already 
prepared NAPDH-cofactor mix and adding 4 ml of acetonitrile (total volume 100 ml).  
The cofactor/ acetonitrile mix (100 µl) was added to the remaining wells 2-12.  Six 
microliters of quinidine (CYP2D6 selective inhibition control inhibitor, 25 µM) or an 
individual test compound (CMT, DEX, MA, and MDMA) were added to well 1 of each 
row (150 µl total volume in well 1).  Test compounds of two or more drugs were added 
equally to well 1 (example: CMT/ MA, 3 µl of CMT and 3 µl of MA was added to well 
1).  Rows 1 and 2 were duplicates and contained quinidine for each plate assayed.  Rows 
3-8 contained one of the test compounds in duplicate (Table 6).  Then each row that 
contained either a test compound or quinidine was serially diluted (1:3) beginning with 
well 1 (50 µl) in succession to well 8.  In order to have a consistent 100 µl (total volume) 
in each well, the excess 50 µl from well 8 was discarded.  No test compounds or 
quinidine were added to wells 9 through 12. Wells 9-10 were the AHMC control 









Table 6.  Sample 96-well plate 
Serial Dilution of test compounds and quinidine 
(columns 1-8) in duplication 
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Rows A and B illustrate concentration values serially diluted ranging from 500 nM to 
0.23 nM for quinidine in duplicate.  C and D illustrate concentration values serially 
diluted ranging from 20 µM to 9 nM for tests compounds of one drug (CMT, DEX, MA, 
or MDMA) in duplicate.  E and F illustrate concentration values of each drug serially 
diluted ranging from 10.0 µM to 4 nM for test compounds with two drugs (CMT/ MA, 
CMT/ MDMA, DEX/ MA, or DEX/ MDMA) in duplicate.  G and H illustrate 
concentration values of each drug serially diluted ranging from 6.67 µM to 3 nM for test 
compounds with three drugs (CMT/ DEX/ MA or CMT/ DEX/ MDMA) in duplicate.  
The dilution factor was 1:3.   
  
The plates were covered with the clear plate lid and pre-incubated for 10 min at 
37
o
C.  After preincubation, the plates were removed and 100 µl of the enzyme/ substrate 
mix was added to wells 1 through 10.  The enzyme/ substrate mix was prepared by 
adding 95 ml of 37
o
C water, 900 µl of CYP2D6*1 + P450 reductase (enzyme), and 36 µl 
of 10 mM AMMC (substrate) to the prewarmed buffer solution.  Plates were incubated 
for 30 min at 37
o
C, and the reaction was stopped by the addition of 75 µl stop reagent 
solution to all wells (total volume 275 µl).   Enzyme/ substrate mix was not added to 
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wells 11- 12, and fluorescence from these wells (11- 12) constituted background 
fluorescence.  Background values were subtracted from the treatment wells.   
III.C. Rats 
Male Sprague-Dawley rats (6 months 375-425 g, Harlan Sprague-Dawley 
Laboratories, Indianapolis, IN) were randomly selected for the process, group housed, 
and allowed access to food and water ad libitum in a temperature controlled room (23+ 
2
o
C) and 12-hour cycle for light and dark.  All animals experienced the same 
environmental conditions over the course of the experiment.  Twenty rats were needed 
for this experiment, n= 4 for each group.   
 
III.D. Drug Administration and Treatment 
Rats were randomly assigned to one of the 5 treatment groups: The first group 
was the control group (naive); the second group was treated with the vehicle (VC; 0.9% 
saline and DMSO); the third group was treated with CMT; fourth group was treated with 
DEX; the fifth group was treated with CMT and DEX.  Each group, except for naive, 
contained 100 µl/ ml of DMSO to promote solubility, 4% DMSO was injected into each 
rat.   Rats were lightly anesthetized in a carbon dioxide gas chamber.  All compounds 
were administered via intraperitoneal (i.p.) injections.  On Day 8 the drug- treated rats 
were challenged with 5 mg/kg (i.p.) injections of MA.  Table 7 summarizes the 
concentrations and groupings used for each treatment.   
After i.p. MA injection (7 h post injection), the rats were lightly anesthetized 
using carbon dioxide gas, and sacrificed by decapitation. The median and the left lateral 
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lobes, the largest lobes of the liver, were harvested from each rat and frozen in liquid 
nitrogen.  Samples were stored at -80
o
C until ready for use.   
 
Table 7. In vivo groupings and concentrations for drug treatments 
Treatment Day 1-7 Day 8 
5mg/ kg MA i.p. 
Naive - - - - - - - - 
Saline (VC) x x x x x x x x 
 CMT 
(10.0 mg/kg  
For 7 days) 
x x x x x x x x 
DEX 
(10.0 mg/kg  
For 7 days) 
x x x x x x x x 
CMT/DEX 
(10.0 mg/kg  
For 7 days; 10.0 
mg/kg  
For 7 days) 
x x x x x x x x 
Naive group not challenged with MA.  Saline, CMT, DEX, CMT/ DEX groups were 
challenged with MA at the end of the seven day treatment period.   
 
III.E. Microsome preparation 
 The microsomal fractions were prepared from stored liver tissue with slight 
modifications as described by Nelson et al., 2001.  The frozen (-80°C) rat livers were 
thawed and minced in homogenizing buffer 2- 4 ml (0.1 M potassium phosphate (pH 7.4) 
and 0.25 M sucrose), then brought to 30 ml with additional homogenizing buffer.  
Homogenization was completed with 10 strokes at 900 rpm using a mechanically driven 
Teflon pestle (GlasCol, Terre Haute, IN) in a glass homogenizer (Wheaton, USA). 
Nuclei and mitochondria were removed by centrifugation at 9,000 g (7659 rpm) 
for 20 min in a Beckman Avanti J-25 centrifuge (Fullerton, CA) at 4°C using a JA-14 
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rotor.   The resulting homogenate was then centrifuged at 100,000x g (24,140 rpm) for 60 
min in a Beckman L7-55 ultracentrifuge (Fullerton, CA) using a Ti-45 rotor. The 
resulting pellet (containing microsomes) was resuspended in 20 ml of incubation buffer 
(0.1 M potassium phosphate (pH 7.4), 0.25 M sucrose, 1 mM EDTA, 5% glycerol) and 
used immediately in the assay, or stored frozen (-80°C) until ready for use.  Florence et 
al. (1982) showed washed microsomes could be stored at -80ºC for up to 30 days without 
loss of activity.  All stored microsomes in the present studies were used prior to the end 
of the 30 day period.   
 
III.F. Protein Analysis  
 Commercially available Bio-Rad Protein Assay (Bio-Rad Life Science Group, 
Richmond, CA) is based on the method of Bradford (1976) and measures the amount of 
protein in a sample.  It involves the addition of an acidic dye (Coomassie® Brilliant Blue 
G-250 dye) to the solution containing proteins, followed by measurement of absorbance 
at 595 nm with a microplate reader or spectrophotometer.  The measured absorbance at 
595 nm is directly proportional to the amount of protein concentration in the sample.   
The acidic blue dye (40 µl) was added to each well of the clear 96- well plate 
(Falcon
TM
, Franklin, NJ).  Microsomal samples (160 µl) were mixed in duplicate with the 
dye.  The plate also contained the standard curve (eight known concentrations of the 
protein standard), bovine serum albumin (BSA), and a blank sample.   Comparison to the 
standard curve was used to interpolate the protein concentration of the test samples.  The 
plate was incubated for five minutes at room temperature and read by the plate reader.  
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Based on specific CYP2D2 activity, the calculations for pmol/ mg protein/ min were 
determined.   
III.G. In vivo Kinetic Studies 
The in vivo kinetic studies used the HTS kit from the in vitro studies but with 
more modifications, described below.  The HTS assay was used to quantify the CYP2D2 
(rat) enzyme activity for each of the drug treatment groups following MA challenge.  
This quantification was done by measuring the reduction of AMMC to AHMC.  Activity 
of CYP2D2 enzyme can be determined following seven day exposure to CMT, DEX, and 
CMT/ DEX, or saline using AMMC as a probe.  This probe has been shown to be highly 
selective for rat CYP2D2 as well as the human CYP2D6 isoform (Stresser et al., 2002).  
The human CYP2D6 enzyme (CYP2D6*1 + P450 reductase) was replaced with 
microsomal fractions containing CYP2D2 in the assay protocol.   
Prior to initiation of the assay, cofactor/ acetonitrile mix was prepared as before 
and (100 µl) was added to wells 1-7 of the 96-well plate.  The enzyme mix for the 
treatment groups was prepared for each microsomal fraction by adding H2O, buffer (0.5 
M potassium phosphate, pH 7.4, filter sterilized), and enzyme (microsomal fraction), a 
79:20:0.75 mix.  The enzyme mix for well 1 (blank) was prepared by adding H2O, buffer, 
and enzyme (CYP2D6 from the HTS kit), also a 79:20:0.75 mix.   The blank well 
contained no AMMC therefore 100 µl of enzyme mix was added to that well.  For the 
treatment groups, 99.7 µl of enzyme mix and 0.3 µl of AMMC (in varying concentrations 
3.29 µM to 0.5 µΜ) was added (total volume 100 µl) to wells 2-7.  Varying AMMC 
concentrations produced a concentration response curve that determined enzyme kinetics.  
The plate was incubated for 30 min at 37
o
C, and the reaction was terminated with the 
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addition of stop reagent (75 µl).  The fluorescence of the blank (well 1) for each test 
group was subtracted from each treatment well.  The fluorescence of the AHMC product 
was read at excitation/emission wavelengths of 360 nm/ 460 nm.  This assay was 
performed in duplicate with a n= 4. 
 
III.H. Solid Phase Extraction and Gas Chromatography/ Mass Spectrometry 
Blood obtained from the jugular, supernatant saved from the microsomal 
preparation, and tissues from the excised brain were used for Solid Phase Extraction 
(SPE) and Gas Chromatography/ Mass Spectrometry (GC/ MS) analysis.  MA was 
extracted using Bond Elut certify SPE columns (Varian, Palo Alto, CA) and analyses 
were done on an Agilent 6890 series GC System (Palo Alto, CA) interfaced with an 
Agilent 5973 Inert Mass Selective Detector (Palo Alto, CA).  
SPE is an accepted method used to extract basic drugs like MA because of its 
reproducibility, minimized solvent usage, and automation. This method creates short, 
adsorbent, fast- flow columns that selectively bind drugs from aqueous mixes.  It allows 
carbohydrates, proteins, and polar lipids to pass through and allows the elution of drugs 
with efficient solvents.  SPE uses silica gel for the stationary phase.    
MA extractions were prepared by mixing various amounts of blood, supernatant 
or brain tissue, dependent on amount collected, with 1 ml of 100 mM potassium 
phosphate buffer (pH 6.0) followed by filtration through a 0.45 µM syringe filter (VWR, 
Batavia, IL).  The column was conditioned using 2 ml of methanol followed by 2 ml of 
100 mM potassium phosphate buffer (pH 6.0).  The sample was added at a flow rate of 2 
ml/ min.  The columns were washed with 6 ml of HPLC grade H2O and 3 ml of 1 M 
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acetic acid immediately following the addition of the sample without letting the column 
dry.  The column dried under vacuum for 5 min at room temperature, followed by a 6 ml 
methanol wash.  The samples were eluted with 2 ml of methylene chloride/ isopropyl 
alcohol (80:20) with 2% ammonium hydroxide and evaporated to dryness in a Speed-Vac 
(Savant, Ramsey, MN) forming a white powder residue.  The resulting residue was stored 
in the -80
o
C freezer until further analysis.   
The residue was reconstituted using ethyl acetate, a common organic solvent used 
for GC/MS.  The GC/ MS was operated in electron impact mode with an ionization 
voltage 70 eV and all other parameters set at autotune values.  A Restek Rxi
TM
-5ms 
(Bellefonte, PA) capillary column (30 m X 0.25 mm ID, 0.25 µm film thickness) was 
used for chromatographic separation.  One microliter splitless injections were made, and 





C, respectively.  Oven temperature was held at 100
o
C 




C/ min and held for 2.00 min.  The carrier gas was 
99.99% pure helium, and the gas line was equipped with moisture, hydrocarbon, and 2 
oxygen traps.  A column head pressure of 10.5 psi gave a helium flow rate of 1.0 mL/ 
min.   Using this method, MA standards eluted at 4.3 min.  The MS detector was operated 
in scan mode detecting m/z 58, 91 and 117 for MA.   
 
III.I. Statistical Analyses 
 For the in vitro CYP2D6 inhibition assay, data was collected as means of 
fluorescence read at excitation/ emission wavelengths of 360 nm/ 460 nm.  To determine 
the percentage of AHMC fluorescence data was calculated by subtracting blank well 
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values from the tested wells then the difference was divided by the highest fluorescence 
value (AHMC fluorescence control, which contained no test compound or quinidine) and 
multiplied by 100.  The inhibitory potency of quinidine and each test compound IC50 
value, inhibitor concentration that causes a decrease in enzyme activity by 50%, was 
determined by nonlinear regression and analyzed using one- way analysis of variance 
(ANOVA) followed by Bonferroni’s multiple comparisons correction as appropriate.  
The maximum inhibition compared to maximum quinidine inhibition was calculated by 
dividing the lowest fluorescence value by the fluorescence control value (for quinidine 
and each test compound) and that resulting value (each test compound percent mean) was 
divided by quinidine percent mean and multiplied by 100.  The quinidine percent mean 
was set at 100.   
 For the in vivo enzyme kinetic assay, data was collected the same as the previous 
study.  Kinetic curve data was calculated by subtracting blank values from the tested 
wells and analyzed using a nonlinear fit of the data.  Vmax, maximum enzyme velocity, 
for each treatment group was calculated using values obtained from the kinetic curves, 
the AHMC standard curve, and the protein assay standard curve.  Then data was analyzed 
using nonlinear regression and one- way ANOVA followed by Bonferroni’s multiple 
comparisons correction as appropriate.  The AHMC and protein standard curves were 
calculated by subtracting the blank values from each test well and analyzed using linear 
regression of the data.  The data from the kinetic curves was transferred to the AHMC 
standard curve and the values interpolated using linear regression.  These values were 
then divided by the amount of protein determined by the protein assay standard curve and 
then divided by the incubation time (30 min).  The treatment group protein values were 
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determined by subtracting the blank value from each test well and interpolated those 
values into the protein standard curve using linear regression of the data.  Km, substrate 
concentration that leads to half the maximum velocity, was calculated using data obtained 
from the kinetic curves and analyzed using nonlinear regression and one- way ANOVA 
followed by Bonferroni’s multiple comparisons correction as appropriate.   
All statistical analyses of data were performed with Prism v5.0 GraphPAD 
Software (San Diego, CA) and considered significant if p< 0.05.  Repetitive experiments 






IV.A. In vitro CYP2D6 Assay  
Determination of inhibitor potency To determine inhibition of CYP2D6 by 
quinidine and test compounds with concentrations ranging from 0.23 to 2.0 x 10
5
 nM, the 
reduction of AHMC fluorescence was measured. Gentest’s CYP2D6/ AMMC high 
throughput inhibitor screening assay was performed to determine the amount of reduced 
AHMC which is proportional to the inhibition.  The inhibitor potency was calculated as 
the inhibition concentration that causes a 50% decrease in enzyme activity (IC50).  The 
IC50 values for quinidine and each test compound (CMT, DEX, MA, MDMA, CMT/ MA, 
CMT/ MDMA, DEX/ MA, DEX/ MDMA, CMT/ DEX/ MA, and CMT/ DEX/ MDMA) 
are listed in Table 8 and graphically represented in Figures 11- 12 expressed as mean + 
S.E.M.  The test compounds’ IC50 values were compared to the quinidine IC50 value (IC50 
value of 3.8 nM), a known potent inhibitor of CYP2D6, and one- way ANOVA reported 
no significant differences, p< 0.05.  This may be because the potency for each of the 
drugs is similar.  Crespi et al. (1997) reported an IC50 value for quinidine of 8.9 nM from 
similar high throughput studies, and Gentest, the manufacturer, reports a value of 11 nM 
for quinidine.  Therefore the assay was performed within the manufacturer’s 
specifications.  The inhibition curves of quinidine and each test compound are
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graphically represented in Figures 13-17.  Quinidine, CMT, MA, MDMA, CMT/ 
MDMA, DEX/ MA, DEX/ MDMA, CMT/ DEX/ MA and CMT/ DEX/ MDMA were 
expressed as n=4 in duplicate since there were four experiment runs with statistical and 
graphical data.  DEX and CMT/ MA were expressed as n=3 in duplicate since one 
experiment run did not provide statistical or graphical data.   
 40 
Table 8. IC50 values for quinidine and each of the treatment groups’ concentrations.                           














3.8 1139 25.2 1.2 36.3 994.3 350.6 24.7 47.9 127.0 77.7 
















































Each test compound and quinidine was assayed to determine the inhibition of the enzyme for that compound.  Increasing 
concentrations (3 nM to 20 µM) of quinidine and each test compound were incubated with CYP2D6 supersomes for 30 min at 37ºC.  
The reduction of AHMC fluorescence was measured and the IC50 value, inhibitor concentration that causes a decrease in enzyme 
activity by 50%, was compared to known IC50 values. The IC50 value was determined by nonlinear regression and analyzed using one- 
way analysis of variance (ANOVA) followed by Bonferroni’s multiple comparisons correction as appropriate.  Each treatment group 





































































































  Figure 11. Each test compound and quinidine was assayed to determine the 
inhibition of the enzyme for that compound.  Increasing concentrations (3 nM to 20 µM) 
of quinidine and each test compound were incubated with CYP2D6 supersomes for 30 
min at 37ºC.  The reduction of AHMC fluorescence was measured and the IC50 value, 
inhibitor concentration that causes a decrease in enzyme activity by 50%, was compared 
to known IC50 values. The IC50 value was determined by nonlinear regression and 
analyzed using one- way analysis of variance (ANOVA) followed by Bonferroni’s 
multiple comparisons correction as appropriate.  Results are expressed as mean + S.E.M., 





































































































Figure 12.  Each test compound and quinidine was assayed to determine the 
inhibition of the enzyme for that compound.  Increasing concentrations (3 nM to 20 µM) 
of quinidine and each test compound were incubated with CYP2D6 supersomes for 30 
min at 37ºC.  The reduction of AHMC fluorescence was measured and the IC50 value, 
inhibitor concentration that causes a decrease in enzyme activity by 50%, was compared 
to known IC50 values. The IC50 value was determined by nonlinear regression and 
analyzed using one- way analysis of variance (ANOVA) followed by Bonferroni’s 
multiple comparisons correction as appropriate.  Results are expressed as mean + S.E.M., 

































































































Figure 13.  Quinidine percent inhibition of CYP2D6 activity.  Increasing 
concentrations (0.23 to 5.0 x 10
2
 nM) of quinidine were incubated with CYP2D6 
supersomes for 30 min at 37ºC.  The reduction of AHMC fluorescence was measured and 
the IC50 value was compared to known IC50 values.  The calculated IC50 value for 
quinidine is 3.8 + 1.3 nM.  The percent of AHMC fluorescence was calculated by 
subtracting blank well values from the tested wells, this difference was then divided by 
the highest fluorescence value (AHMC fluorescence control, contained no test compound 
or quinidine) and multiplied by 100.  Data expressed as total inhibition mean + S.E.M., 






































































































Figure 14.  CMT percent inhibition of CYP2D6 activity.  Increasing 
concentrations (9.0- 2.0 x 10
4
 nM) of CMT were incubated with CYP2D6 supersomes for 
30 min at 37ºC.  The reduction of AHMC fluorescence was measured and the IC50 value 
was compared to the quinidine IC50 value. The calculated IC50 value for CMT is 1139 + 
1137 nM.  The percent of AHMC fluorescence was calculated by subtracting blank well 
values from the tested wells, this difference was then divided by the highest fluorescence 
value (AHMC fluorescence control, contained no test compound or quinidine) and 







































































































Figure 15.  Representative DEX percent inhibition of CYP2D6 activity.  
Increasing concentrations (9.0- 2.0 x 10
4
 nM) of DEX were incubated with CYP2D6 
supersomes for 30 min at 37ºC.  The reduction of AHMC fluorescence was measured and 
the IC50 value was compared to the quinidine IC50 value.  The calculated IC50 value for 
DEX is 25.2 + 25.1 nM.  The percent of AHMC fluorescence was calculated by 
subtracting blank well values from the tested wells, this difference was then divided by 
the highest fluorescence value (AHMC fluorescence control, contained no test compound 
or quinidine) and multiplied by 100.  Data expressed as total inhibition mean + S.E.M., 






































































































Figure 16.  MA percent inhibition of CYP2D6 activity.  Increasing 
concentrations (9.0- 2.0 x 10
4
 nM) of MA were incubated with CYP2D6 supersomes for 
30 min at 37ºC.  The reduction of AHMC fluorescence was measured and the IC50 value 
was compared to the quinidine IC50 value.  The calculated IC50 value for MA is 1.2  + 4.0 
nM.  The percent of AHMC fluorescence was calculated by subtracting blank well values 
from the tested wells, this difference was then divided by the highest fluorescence value 
(AHMC fluorescence control, contained no test compound or quinidine) and multiplied 









































































































Figure 17. MDMA percent inhibition of CYP2D6 activity.  Increasing 
concentrations (9.0- 2.0 x 10
4
 nM) of MDMA were incubated with CYP2D6 supersomes 
for 30 min at 37ºC.  The reduction of AHMC fluorescence was measured and the IC50 
value was compared to the quinidine IC50 value.  The calculated IC50 value for MDMA is 
36.3 + 19.5 nM.  The percent of AHMC fluorescence was calculated by subtracting blank 
well values from the tested wells, this difference was then divided by the highest 
fluorescence value (AHMC fluorescence control, contained no test compound or 
quinidine) and multiplied by 100.  Data expressed as total inhibition mean + S.E.M., n= 4 







































































































Figure 18. Representative percent inhibition of CYP2D6 activity for CMT 
combined with MA or MDMA.  Increasing concentrations (4.0- 1.0 x 10
4
 nM) of each 
test compound (CMT/ MA and CMT/ MDMA) were incubated with CYP2D6 
supersomes for 30 min at 37ºC.  The reduction of AHMC fluorescence was measured and 
the IC50 values were compared to the quinidine IC50 value.  The calculated IC50 value for 
CMT/ MA is 994  + 993 nM.  The IC50 value for CMT/ MDMA is 351 + 186 nM.  The 
percent of AHMC fluorescence was calculated by subtracting blank well values from the 
tested wells, this difference was then divided by the highest fluorescence value (AHMC 
fluorescence control, contained no test compound or quinidine) and multiplied by 100. 







































































































Figure 19.  Percent inhibition of CYP2D6 activity for DEX combined with MA 
or MDMA.  Increasing concentrations (4.0- 1.0 x 10
4
 nM) of each test compound (DEX/ 
MA and DEX/ MDMA) were incubated with CYP2D6 supersomes for 30 min at 37ºC.  
The reduction of AHMC fluorescence was measured and the IC50 values were compared 
to the quinidine IC50 value.  The calculated IC50 value for DEX/ MA is 24.7 + 24.6 nM.   
The IC50 value for DEX/ MDMA is 47.9 + 26.3 nM.  The percent of AHMC fluorescence 
was calculated by subtracting blank well values from the tested wells, this difference was 
then divided by the highest fluorescence value (AHMC fluorescence control, contained 
no test compound or quinidine) and multiplied by 100.  Data expressed as total inhibition 








































































































Figure 20.  Percent inhibition of the effects of CMT/ DEX combined with MA 
and CMT/ DEX combined with MDMA on CYP2D6 activity.  Increasing concentrations 
(3.0 to 6.67 x 10
3
 nM) of each test compound (CMT/ DEX and MA or CMT/ DEX and 
MDMA) were incubated with CYP2D6 supersomes for 30 min at 37ºC.  The reduction of 
AHMC fluorescence was measured and the IC50 values were compared to the quinidine 
IC50 value.  The calculated IC50 value for CMT/ DEX and MA is 1270 + 1185 nM.  The 
IC50 value for CMT/ DEX and MDMA is 77.8 + 46.4 nM.  The percent of AHMC 
fluorescence was calculated by subtracting blank well values from the tested wells, this 
difference was then divided by the highest fluorescence value (AHMC fluorescence 
control, contained no test compound or quinidine) and multiplied by 100.  Data expressed 
as total inhibition mean + S.E.M., n= 4 in duplicate.  
 
 
Determination of maximum inhibition compared to quinidine To compare the 
test compounds to maximum quinidine inhibition the data obtained from the CYP2D6 
assay was used, and quinidine inhibition was set at 100 thus the test compounds became a 
percentage of it.  Maximum inhibition of CYP2D6 activity in the presence of test 
compounds’ [CMT, CMT/ MA, DEX/ MA, CMT/ DEX/ MA, and CMT/ DEX/ MDMA 
(F10, 43= 4.976, p<0.05)] compared to maximum quinidine inhibition decreased 
significantly from quinidine and CMT/ MDMA inhibition (Figure 21).  Maximum MA 
(F10, 43= 4.976, p<0.05) inhibition significantly decreased compared to maximum 
quinidine inhibition (Figure 21).  The test compounds maximum inhibition [CMT, MA, 
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CMT/ MA, DEX/ MA, CMT/ DEX/ MA, and CMT/ DEX/ MDMA] showed a 75-85% 
decrease compared to maximum quinidine inhibition.  This suggests that the test groups 
inhibited CYP2D6 significantly less than quinidine.  This may be because the efficacy for 




































































































































































































Figure 21.  Maximum inhibition compared to quinidine was determined from 
data obtained from the CYP2D6 assay.  Quinidine inhibition percentage was set at 100 
thus the test compounds became a percentage of it.  The dotted line represents quinidine.  
Maximum CMT, CMT/ MA, DEX/ MA, CMT/ DEX/ MA and CMT/ DEX/ MDMA 
inhibition compared to maximum quinidine inhibition decreased significantly from 
quinidine and CMT/ MDMA inhibition.  Maximum MA inhibition decreased 
significantly compared to maximum quinidine inhibition.  Results are expressed as a 
percentage of the maximum quinidine inhibition of the mean + S.E.M.  (n= 4 in duplicate 
for quinidine and all test compounds) *p< 0.05 when compared to quinidine, 
+
p< 0.05 








IV. B. In Vivo Assay 
 Determination of enzyme velocity To determine Vmax, the maximum enzyme 
velocity, values obtained from the kinetic curves (Figures 23-28), the AHMC standard 
curve (Figure 29), and the protein assay standard curve were used (Figure 30).  The Vmax 
value in the CMT treated group increased significantly from naive (F4, 15= 4.344: p< 
0.05).  However, all MA treated groups showed very high increases (280- 490%) from 
naive.  The Vmax values for all experimental groups are listed in Table 9 and Figure 22 
illustrates the graphical representation.  Saline, DEX, and CMT/ DEX were expressed as 
n= 4 in duplicate since there were four experimental runs with statistical and graphical 
data.  Naive and CMT graphs (Figures 23, 24, and 26) are expressed as n= 5 but 
calculations are expressed as n= 4 in duplicate since one run provided graphically data 
but no statistical data.   
 
Table 9.  Vmax values for each treatment groups. 
Treatment 
 





19.92 65.86 98.28 70.46 56.38 
S.E.M. 
 





























































































Figure 22.  Vmax values were determined from the data obtained from the kinetic 
curves, the AHMC standard curve, and the protein assay standard curve.  Then data was 
analyzed using nonlinear regression and one- way ANOVA followed by Bonferroni’s 
multiple comparisons correction as appropriate.  Data from the kinetic curves was 
transferred to the AHMC standard curve and the values interpolated using linear 
regression, this determined the pmol values.  These values were then divided by the 
amount of protein determined by the protein assay standard curve and then divided by the 
incubation time (30 min).  The treatment group protein concentrations (mg) were 
determined by interpolating the values into the protein standard curve using linear 
regression of the data.  CMT increased significantly compared to naive.  Results are 
expressed as mean + S.E.M., n= 4 in duplicate for all treatments groups, *p< 0.05 when 





















































Figure 23.  Kinetic analysis of CYP2D2 activity in rat microsomes.  Increasing 
concentrations (0.05 to 3.29 µM) of AMMC were incubated with CYP2D2 from each 
treatment group for 30 min at 37
o
C.  Reduction of AMMC to AHMC fluorescence was 
measured, Km values obtained, and Vmax values determined with calculations.  Data 
expressed as mean + S.E.M., n= 4 in duplicate for saline, DEX, and CMT/DEX and n= 5 
in duplicate for naive and CMT.  
  
 
















































Figure 24.  Naive kinetic analysis of CYP2D2 activity in rat microsomes.  
Increasing concentrations (0.05 to 3.29 µM) of AMMC were incubated with CYP2D2 
from the naive for 30 min at 37
o
C.  Reduction of AMMC to AHMC fluorescence was 
measured, Km values obtained, and Vmax values determined with calculations.  Calculated 
Vmax and Km values for the naive group, 19.92 + 5.084 pmol/ mg protein/ min and 3.081 
+ 0.459 µM, respectively with a R
2
 value of 0.9436.  Data expressed as mean, n= 5 in 
duplicate for graphing purposes and n= 4 in duplicate for calculations.     
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Figure 25.  Saline kinetic analysis of CYP2D2 activity in rat microsomes.  
Increasing concentrations (0.05 to 3.29 µM) of AMMC were incubated with CYP2D2 
containing saline for 30 min at 37
o
C.  Reduction of AMMC to AHMC fluorescence was 
measured, Km values obtained, and Vmax values determined with calculations.  Calculated 
Vmax and Km values for the saline group, 65.86 + 12.02 pmol/ mg protein/ min and 6.806 
+ 0.733 µM, respectively with a R
2
 value of 0.9439.  Data expressed as mean, n= 4 in 
duplicate.     
 
















































Figure 26.  CMT kinetic analysis of CYP2D2 activity in rat microsomes.  
Increasing concentrations (0.05 to 3.29 µM) of AMMC were incubated with CYP2D2 
containing CMT for 30 min at 37
o
C.  Reduction of AMMC to AHMC fluorescence was 
measured, Km values obtained, and Vmax values determined with calculations.  Calculated 
Vmax and Km values for the CMT group, 98.28 + 22.09 pmol/ mg protein/ min and 6.728 
+ 1.341 µM, respectively with a R
2
 value of 0.9757.  Data expressed as mean, n= 5 in 
duplicate for graphing purposes and n= 4 in duplicate for calculations.         
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Figure 27.  DEX kinetic analysis of CYP2D2 activity in rat microsomes.  
Increasing concentrations (0.05 to 3.29 µM) of AMMC were incubated with CYP2D2 
containing DEX for 30 min at 37
o
C.  Reduction of AMMC to AHMC fluorescence was 
measured, Km values obtained, and Vmax values determined with calculations.  Calculated 
Vmax and Km values for the DEX group 70.46 + 15.05 pmol/ mg protein/ min and 6.397 + 
0.465 µM, respectively with a R
2
 value of 0.9443.  Data expressed as mean, n= 4 in 
duplicate.     
 















































Figure 28.  CMT/ DEX kinetic analysis of CYP2D2 activity in rat microsomes.  
Increasing concentrations (0.05 to 3.29 µM) of AMMC were incubated with CYP2D2 
containing CMT/ DEX for 30 min at 37
o
C.  Reduction of AMMC to AHMC fluorescence 
was measured, Km values obtained, and Vmax values determined with calculations.  
Calculated Vmax and Km values for the CMT/ DEX group 56.38 + 6.096 pmol/ mg 
protein/ min and 5.087 + 0.547 µM, respectively with a R
2
 value of 0.9492.  Data 
expressed as mean, n= 4 in duplicate.     
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Figure 29.  Standard curve of AHMC used to interpolate Vmax values.  Increasing 
concentrations (0.03 to 2.5 pmol) of AHMC fluorescence was measured and the blank 
values subtracted from each test well.  The data was analyzed using linear regression.  
The line has a R
2







































Figure 30.  Standard curve for the Bio-Rad Protein assay used to interpolate Vmax 
values.  Increasing concentrations (3.125 to 150.00 µg/ ml) of bovine serum albumin 
(BSA) absorbance at 595 nm was measured.  The data was analyzed using linear 
regression.  The line has a R
2





Determination of Km To calculate Km, the substrate concentration that leads to 
half of the maximum velocity, data obtained from the kinetic curves and the nonlinear 
analysis were used (Figures 23-28).    The Km value in the CMT and saline treated groups 
increased significantly compared to the naive group (F4, 15= 4.071, p<0.05, Figure 31).  
Comparison within the treatment groups reported no significant differences compared to 
naive.  All the MA treated groups showed very high increases (165- 220%) from naive.  
This suggests that MA administration resulted in an increase in Km by 2 fold.  This means 
that 2x the substrate amount is needed to reach a ½ max response.  The Km values are 
listed in Table 10.  All calculations are expressed as n= 4 in duplicate. 
 
Table 10.  Km values for each treatment groups. 
Treatment 
 




3.081 6.806 6.728 6.397 5.087 
S.E.M. 
 





































































































Figure 31.  Km values were determined from kinetic analysis of each treatment 
group.  Then data was analyzed using nonlinear regression and one- way ANOVA 
followed by Bonferroni’s multiple comparisons correction as appropriate.  CMT and 
saline were significantly different from the naive group.  Results are expressed as mean + 




IV. C. Gas Chromatography and Mass Spectrometry 
 
 Determination of MA levels in vivo To detect MA, source samples of blood 
obtained from the jugular, supernatant saved from the microsomal preparation, and brain 
tissue were used.  MA was extracted using SPE, reconstituted in ethyl acetate, and then 
injected onto the GC/ MS.  MA standards eluted at approximately 4.3 min (Figure 32), 
and MA ions were detected at 58, 91, and 119 m/z (Figure 33).  Our limit of detection 
(LOD) was 1271.48 + 191.69 ng, and the limit of linearity (LOL) was 5.0 x 10
5 
ng.  The 
limits were calculated from the standard curve of MA (Figure 34) and the baseline.  
However, none of the samples showed a MA peak.  This problem was most likely due to 
MA in the samples below the LOD; and since MA distributes throughout the body in rats 
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with a Vd range of 1.26 to 9.0L/ kg (Figure 35) (Kitaichi et al., 2004; Riviere et al., 
1999).  To achieve levels that are above the LOD the rats should have been sacrificed at 
the half-life for rats t1/2= 1 hr (Milesi- Halle et al., 2005) not the half-life for humans t1/2= 
7- 10 hrs (Logan, 2002).  The percentage of MA remaining after 7 hrs was 0.78 %.   
 
 
Figure 32.  Representative standard MA chromatogram. MA eluted at 4.3 min with 
an abundance of 450,000.  This correlates to 125,000 ng in the MA standard.  The GC 
system was an Agilent 6890 series interfaced with an Agilent 5973 inert mass selective 
detector. The column used was a Restek Rxi
TM
- 5ms capillary column (30m X 0.25 mm 
i.d., 0.25 µm film thickness).  The sample was injected in the splitless mode and the oven 
temperature was set at 100
o




C/ min & held for 2.00 
min.   
 





Figure 33.  Representative MA spectrum (top) and corresponding library match 
spectrum (bottom).  The top spectrum shows MA ions detected at 58, 91 and 119 m/z 
































Figure 34. Standard curve of MA used to determine LOD and LOL. Increasing 
concentrations (3906.25 to 500,000 ng) of MA were measured.  The data was analyzed 
using linear regression.  The MA standard line has a slope value of 5.702 + 0.0998 ng/ 
abundance. The baseline has a slope of 0.0117 + 0.0053 ng/ abundance.  The LOD value 
was determined to be 1271.48 + 191.69 ng, and the LOL was 5.0 x 10
5 
ng.   
 





















Figure 35.  Volume of distribution for MA in rats has been reported to vary 
widely.  The data was analyzed using linear regression.  These values were obtained from 
Riviere et al., 1999 (0.1 mg/ kg has a Vd of 9.3 + 1.3 L/ kg and 1.0 mg/ kg has a Vd of 
9.0 + 2.0 L/ kg), Kitaichi et al., 2004 (5 mg/ kg has a Vd of 6.73 + 1.32 L/ kg), and 
Hutchaleelaha et al., 1996 (15 mg/ kg has a Vd of 2.64 + 1.16 L/ kg).  The slope of the 
line is -0.4494 + 0.0219 and an R
2




Figure 36.  Representative MA sample for all source samples (brain tissue, 
supernatant, and blood).  No MA peak was observed, since the MA concentration was 
below the LOD 1271.48 + 191.69 ng.  This was due to sacrificing the rats 7 hrs after the 









V. A. Introduction 
The scheduled drugs MA and MDMA are addictive stimulant drugs.  This 
addictive potential of these drugs has been reported, therefore, MA is a schedule II drug 
(addictive and medicinal use), and MDMA is a schedule I drug (addictive and no 
medicinal use).  These drugs are still widely used and easily obtainable.  Therefore 
polydrug use is a growing concern.  The current study examined this concern involving 
the combination of the two scheduled drugs, MA and MDMA, and two common and 
inexpensive OTC drugs, CMT and DEX.  CMT is a histamine blocker that reduces the 
production of stomach acid and is found only as Tagamet®.  DEX is a dextrorotary 
morphinan since it does not bind to opioid receptors but does have a high affinity for 
sigma site ligand receptors and a lower affinity for the PCP receptor; it is found in most 
OTC cold and cough medications as an antitussive.   
 The purpose of this study was to determine the interactions at CYP2D6 between 
the OTC drugs, CMT and DEX, and two scheduled drugs, MA and MDMA when 
administered concurrently.  The initial study examined the inhibition of the isozyme 
CYP2D6 activity caused by each of the drugs individually and in combination.  This 
study determined the concentrations of drugs to be used in the in vivo study.  The in vivo 
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study measured the kinetics of CYP2D6 Vmax and Km, the maximum velocity of the 
reaction and the substrate concentration at which the reaction velocity is 50% of the 
maximum velocity, respectively, by indirectly looking at the effects using the reduction 
of AMMC to AHMC.   
Overall findings in vitro, calculated IC50 values for the test compounds were not 
significantly different when compared to quinidine and each other.  Maximum inhibition 
compared to maximum quinidine inhibition showed that CMT, CMT/ MA, DEX/ MA, 
CMT/ DEX/ MA and CMT/ DEX/ MDMA decreased significantly from quinidine and 
CMT/ MDMA inhibition, a 75- 85% decrease compared to quinidine.  Maximum MA 
inhibition decreased significantly compared to maximum quinidine inhibition.  Inhibitory 
potential (IC50) and maximum inhibition studies compared each test compound to 
quinidine inhibition and maximum quinidine inhibition values.  This comparison 
indicated that each test compound inhibited CYP2D6 activity to some extent.  This 
inhibition data gives relevance to the in vivo study.  Overall findings in vivo, The Vmax 
value in the CMT treated group decreased significantly when compared to naive.  The Km 
values in the CMT and saline treated groups decreased significantly when compared to 
naive.  All MA challenged groups showed increases in Vmax (280- 490%) and Km (165- 
220%) values compared to the naive group.  Therefore, Ma challenge resulted in an 
increase in both kinetic parameters suggesting that the low affinity/ high capacity 





V. B. In Vitro Assay 
 In order to determine the inhibition of CYP2D6 isozyme caused by the OTC and 
scheduled drugs, it was first necessary to determine concentrations that would cause 
inhibition of the isozyme.  The initial concentrations were chosen from a review of the 
literature, and inhibition of the enzyme activity was determined using the CYP2D6/ 
AMMC high throughput inhibition screening assay.   
 The test groups did inhibit CYP2D6 activity but the IC50 values were not 
significantly different from quinidine.  The IC50 value for quinidine of 0.0038 µM was 
consistent with the value reported by the manufacturer, Gentest.  Others have shown that 
quinidine is an effective inhibitor with a range of 0.41 µM to 0.0089 µM dependent on 
substrate and product concentrations (Taavitsainen et al., 2000; Yamamoto et al., 2002; 
and Crespi et al., 1997).  The test compound’s [CMT, CMT/ MA, DEX/ MA, CMT/ 
DEX/ MA, and CMT/ DEX/ MDMA] maximum inhibition significantly decreased 
compared to maximum quinidine and CMT/ MDMA inhibition.  Maximum MA 
inhibition significantly decreased compared to maximum quinidine inhibition.  This data 
showed there was an effect on the catalytic activity of CYP2D6.  Suggesting that all the 
test compounds caused some level of inhibition of CYP2D6, i.e. weak inhibition, 
therefore further studies are relevant.  A review of literature uncovers a few studies 
reporting effects of MA or MDMA on CYP2D6 activity (Taavitsainen et al., 2000; Van 
et al., 2006; Wu et al., 1997; Heydari et al., 2004).  However, MA and MDMA studies 
used different substrates or kinetic parameters like kinact (maximal rate of enzyme 
inactivation) and KI (inhibitor concentration that supports half the maximal rate of 
inactivation) to determine the enzyme activity.  Taavitsainen et al. (2000) reported an 
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IC50 value for MA of 414 µM, but this study used DEX as the substrate probe not 
AMMC.  Heydari et al. (2004) reported MDMA’s rate of activation is decreased when 
quinidine is added.  Studies that include CMT use different methods like Western blot 
analysis with serum containing anti-CYP2D6 (Orishiki et al., 1994) and use different 
factors to determine the kinetic parameters for CMT (Madeira et al., 2003; Martinez et 
al., 1999).  DEX has the most studies on its effects of CYP2D6, and these studies use 
DEX as a probe to determine enzyme activity or phenotyping (Frank et al., 2007; 
Madeira et al., 2003; Martinez et al., 1999).  Also DEX has been used to determine the 
type of metabolizer an individual is (Kerry et al., 1994).  Studies on DEX inhibition 
report IC50 values for DEX of 1.89 µM to 2.0 µM (Yamamoto et al., 2002; Chauret et al., 
2001) dependent on drug concentration.   
 
V. C. In Vivo Assay 
 It is important to know how the drugs will affect CYP2D6 activity in vivo.  Rats 
were injected for seven days with one of the four treatment groups.  On the eighth day, 
rats were challenged with MA, and then sacrificed after 7 hrs.  The livers harvested from 
the rats contain CYP2D2 isozyme.  The CYP2D6 assay was modified to include the rat 
isozyme instead of CYP2D6.  Then GC/ MS analysis was performed to determine the 
metabolized concentration of MA.  The concentrations for the treatment groups were 
determined from the in vitro study.  The concentrations for analysis CMT, DEX and 
CMT/ DEX were 10 mg/ kg for seven days for each drug.  One i.p. injection of 5 mg/ kg 
was used for MA.     
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 The CYP2D6 assay was modified by replacing human CYP2D6 with rat CYP2D2 
microsomes.  The reduction of AMMC to AHMC was measured at varying 
concentrations to determine the Vmax and Km values.  The Vmax value in the CMT treated 
group increased significantly from naive, however, all MA treated groups showed an 
increase in Vmax values (280- 490%).  The Km values in the CMT and saline treated 
groups increased significantly when compared to naive, but again all groups treated with 
MA showed an increase in Km values when compared to naïve (165- 220%).  This 
suggests an overall trend, MA caused the increase in CYP2D6 activity and no effect was 
seen due to the OTC drugs. This data implies that MA may be an inducer via CYP2D2.  
Dostalek et al. (2005) suggests that MA may be an inducer of DEX metabolism via 
CYP2D2; therefore the co-administration of MA with DEX may result in decreased drug 
plasma levels thus a decrease in drug effects.  The Km value in the naive group was 
consistent with the Km value determined by Gentest (1 µM).  This suggests that the 
results from both assays are relevant to each other and can be compared.  Most studies 
that measure enzyme activity of CYP2D6 or CYP2D2 use DEX as the substrate (Van et 
al., 2006), but this study uses the reduction of AMMC to AHMC to determine the 
enzyme activity.  A few studies report the kinetic parameters for MA, CMT and DEX, 
but most use different methods or in vitro instead of in vivo (Lin et al., 1997; Madeira et 
al., 2004).  Lin et al. (1997) report Vmax and Km values for MA, but the values are for 
both isomers of MA and both types of reactions (4-hydroxylation and N-demethylation) 
whereas this study did not differentiate between the two isomers or the two types of 
reactions.  Madeira et al. (2004) report Vmax and Km values for CMT but the study is done 
in vitro instead of in vivo and with DEX as the probe.   
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V. C. i. In vivo GC/MS 
 The GC/ MS analysis is used to identify chemical compounds.  Source samples of 
blood obtained from the jugular, supernatant saved from the microsome preparation, and 
excised brain tissue were used for analysis by the GC/ MS. Unfortunately; no MA was 
detected in the source samples.  This problem was most likely due to MA in the samples 
below the LOD because the rats were sacrificed 7 half-lives after the MA challenge.  The 
LOD was determined to be 1271.48 + 191.69 ng and the limit of linearity (LOL) was 5.0 
x 10
5
 ng.  Rats have a short MA half-life (t1/2= 1 hr) compared to humans (t1/2= 7-10 hrs) 
for that reason the rats should have been sacrificed an hour after injection (Milesi- Halle 
et al., 2005).  Therefore, after 7 hrs, MA in rats is not detectable.  MA distributes 
throughout the body in rats with a wide range of Vd values (Segal et al., 2005).  These 
values range from 1.26 to 9.0 L/ kg (Kitaichi et al., 2004; Riviere et al., 1999).  Peak 
plasma levels in rats after 1 hr have been reported an average of 362 ng/ mL after a 5 mg/ 
kg i.v. (Kitaichi et al., 2004; Fujimoto et al., 2007).  After 3 mg/ kg i.p. administration, 
plasma levels have been reported of 200 ng/ mL (Okuda et al., 2004: Table 11).   
 
Table 11.  Plasma levels for MA in rats after one hour.   
MA dose Route Plasma level Reference 
 
5 mg/kg  i.v. 375 ng/ mL  Kitaichi et al., 2004 
 
5 mg/ kg i.v. 350 ng/ mL  Fujimoto et al., 2007 






V. D. Summary  
 CYP2D6 is an important area of research due to the large role it plays in 
metabolism, its genetic polymorphisms among humans, and its large number of 
substrates.  The chances of a drug- drug interaction are possible.  People need to be aware 
of what can happen when drugs are co-administered, especially when taking scheduled 
drugs.  Since MA and MDMA are popular and easily obtainable, drug- drug interactions 
are probable.  This study determined that the inhibitor potency of all test compounds and 
quinidine were relatively the same.  It was determined that some maximum test 
compounds inhibition decreased significantly compared to maximum quinidine and 
CMT/ MDMA inhibition.  This suggests that all the test compounds inhibited CYP2D6 
activity; one or all of the drugs may not be metabolized as quickly resulting in toxicity of 
those drugs.  The quinidine IC50 value was consistent with reported values.  This 
indicates that the CYP2D6 was performed in accordance to the manufacturer’s 
specifications.  The Vmax value in the CMT treated group increased significantly 
compared to naive.  The Km values in the CMT and saline treated group increased 
significantly compared to naive. Both kinetic parameters showed there was an increase 
after the MA challenge but no effects due to the OTC drugs.   This suggests that the low 
affinity/ high capacity CYP2D2 isoform was upregulated caused by the excess drugs 
meaning that more enzyme was present to help metabolize the drugs.  This implies that 
MA is an inducer via CYP2D2.  This is important to know if MA is an inducer via 
CYP2D2 the rat isoform or is this also true for CYP2D6 the human isoform, especially 
when DEX is co- administered.  This information is imperative since DEX can be used as 
a recreational drug at high concentrations, thus if the two are combined DEX metabolism 
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may be increased causing a decrease in the effects of the drug, therefore causing an 
increase in use and abuse.  No data was obtained from the GC/ MS analysis, due to the 
LOD 1271.48 + 191.69 ng.   
 
V. E. Future Studies 
Further studies need to be conducted to determine how these drugs interact at 
higher concentrations of MA, CMT or DEX.  It would be interesting to know what 
happens in vivo with more than one MA injection.  Another study to be conducted will 
examine if MA is an inducer of DEX via CYP2D6.  This information is imperative since 
DEX metabolism may be increased causing a decrease in the effects of the drug, and 
possibly resulting in an increase in use and abuse.  The in vivo study could be replicated 
using MDMA instead of MA to determine if and how CMT and DEX affects MDMA.  
Also to achieve GC/ MS results the rats should be sacrificed after 1 hr of being injected 
with MA.   
Another aspect that should be examined is the effects of co-administering OTC 
drugs on the metabolism of MA in poor metabolizers vs. extensive metabolizers.  The 
effects of the combination of the two OTC drugs and MA would be interesting, since 
both OTC drugs are inexpensive and MA is easy to obtain.   
Another area of study that would be interesting is to examine if co-administration 
of antidepressants and scheduled drugs affect the metabolism of each other.  If there is an 
effect what type of effect, or drug- drug interactions occur.  This information is a 
significant area of study, since users may want to try to increase the effects of one of the 
drugs.  
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V. F. Summary of Conclusions 
• CYP2D6 in vitro assay studies indicated there were no differences in test group 
IC50 values of CYP2D6 activity.  The IC50 value for quinidine was consistent with 
reported values meaning that the assay is performed to the manufacturer’s 
specifications. The test compounds [CMT, CMT/ MA, DEX/ MA, CMT/ DEX/ 
MA, and CMT/ DEX/ MDMA] maximum inhibition decreased significantly from 
maximum quinidine and CMT/ MDMA inhibition, a 75-85% decrease compare to 
maximum quinidine inhibition.  Maximum MA inhibition decreased significantly 
from maximum quinidine inhibition.  This data suggests that all the test 
compounds inhibited CYP2D6 activity; one or all of the drugs may not be 
metabolized as quickly resulting in toxicity of those drugs.    
• CYP2D2 in vivo assay studies indicated the Vmax value in the CMT treated group 
and the Km values in the saline and CMT treated groups increased significantly 
compared to naive.  However, all MA treated groups showed an increase 
compared to naive. This increase in both parameters suggests that there was an 
overall effect after the MA challenge.  Thus, no effect was caused by the OTC 
drugs.  There seems to be a low affinity/ high capacity enzyme contributing, 
suggesting that more enzyme was present to metabolize the excess drugs after 
MA was administered.  This suggests that MA is an inducer via CYP2D2. 
• GC/ MS indicated the MA extracted from the blood, supernatant, and brain tissue 
samples were below the LOD, therefore no MA was detectable after 7 hrs.  This 
lack of detection is due to the half-life of MA for rats (t1/2= 1 hr).  The LOD was 
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Scope and Method of Study: Drug- drug interactions between over- the- counter (OTC) 
and scheduled drugs may occur at cytochrome P450, which can lead to toxicity 
and possibly death.  This study examined the effects of two OTC drugs, 
cimetidine (CMT) and dextromethorphan (DEX), and two scheduled drugs, 
methamphetamine (MA) and 3, 4-methylenedioxymethamphetamine (MDMA) at 
CYP2D6.  Purified human CYP2D6 was used to determine the inhibitory 
potential (IC50) of the drugs in vitro.  This assay examined the conversion of 
AMMC to its fluorescent metabolite product, AHMC.  Enzyme kinetics was 
conducted to determine Vmax and Km values in vivo using rat microsome CYP2D2 
isozyme.  Solid phase extraction was used to extract MA from liver supernatant 
using Varian Bond Elut columns.  GC/ MS was performed on the extracted MA 
samples to examine changes in MA metabolism following exposure to CMT or 
DEX.    
 
Findings and Conclusions: In vitro, the IC50 values for the test compounds and CYP2D6 
activity were not different compared to quinidine IC50 value.  Maximum 
inhibition of CYP2D6 activity in the presence of test compounds [CMT, CMT/ 
MA, DEX/ MA, DEX/ MDMA, CMT/ DEX/ MA and CMT/ DEX/ MDMA] 
compared to maximum quinidine inhibition decreased significantly from 
quinidine and CMT/ MDMA inhibition, a 75-85% decrease compared to 
quinidine.  Maximum MA inhibition was significantly decreased compared to 
maximum quinidine inhibition.  This data suggests that all the test compounds 
inhibited CYP2D6 activity; one or all of the drugs may not be metabolized as 
quickly resulting in toxicity of those drugs.   In vivo CYP2D2 studies showed that 
the Vmax value in the CMT treated group (98.28 + 22.09 pmol/ mg protein/ min) 
increased significantly compared to naive (19.92 + 5.084 pmol/ mg protein/ min).  
The Km value in the saline (6.806 + 0.73 µM) and CMT (6.728 + 1.341 µM) 
treated groups increased significantly compared to naive (3.081 + 0.46 µM).  All 
MA challenged groups showed increases in Vmax (280- 490%) and Km (165- 
220%) values compared to the naive group.  Therefore, MA challenge resulted in 
an increase in both kinetic parameters (Vmax and Km) suggesting that the low 
affinity/ high capacity CYP2D2 isoform was upregulated.  This data suggests that 
MA is an inducer via CYP2D2, which will lead to altered drug metabolism and an 
alteration of the drug’s effects. 
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